Veran Medical Technologies

The core of Veran's offering is the SPiN Thoracic Navigation System®, an electromagnetic navigation platform. This system functions similarly to a GPS, converting patient CT scans into detailed, 3D virtual maps of the lungs. This allows physicians to navigate through the complex airway system to locate and biopsy suspicious peripheral pulmonary lesions. Key features include "Always-On Tip Tracked" instruments with embedded electromagnetic sensors for precise guidance and Respiratory Gating technology, which accounts for nodule movement as a patient breathes.

A significant differentiator for the company is its SPiN Perc® technology, which enables a seamless transition from a standard navigated bronchoscopy to a navigated transthoracic needle aspiration (TTNA) within a single procedure. This dual-approach capability is crucial for accessing the approximately 40% of lung nodules that lie outside of an airway, thereby eliminating the need for separate procedures and potentially accelerating time to diagnosis. The business model centers on the sale of this integrated system and associated disposable instruments to hospitals and leading cancer centers.

In a significant milestone, Veran Medical Technologies was acquired by Olympus Corporation in December 2020 for up to $340 million. This acquisition integrated Veran's navigation technology into Olympus's broader portfolio of respiratory and endoscope systems, aiming to enhance solutions for diagnosing peripheral lung cancer. At the time of the acquisition, the company was led by CEO Jason Pesterfield.